Introduction

As advances occur in surgical technique, postoperative care, and immunosuppressive therapy, the rate of mortality in the early postoperative period following lung transplantation continues to decline [1].

With the improvements in immediate and early posttransplant mortality, infections and their sequel as well as rejection and chronic allograft dysfunction are increasingly a major cause of posttransplant mortality [2–5].

This chapter will focus on infections by respiratory viruses and other viral infections relevant to lung transplantation, including data regarding the link between viral infections and allograft dysfunction.

Factors Related to Risk of Respiratory Viral Infections

Lungs are the most prone to infection of all solid organ transplantations [2, 4]. This reality is based on multiple factors related and unique to lung transplantation [1, 2]. The lungs are continually exposed to both new environmental pathogens and the colonized native upper airways. Furthermore, many of the natural defense mechanisms of the respiratory system are made ineffective by both the technical aspects of lung transplantation and the relatively increased degree of immunosuppression required to minimize high rates of acute and chronic rejection seen in lung transplantation compared to other solid organs [1, 2, 6, 7].

The usual physical barriers of the respiratory tract against infections include the presence of the mucociliary escalator that traps and expels infectious organisms. These mechanisms are facilitated by the integrity of the epithelium lining the trachea, bronchi, and small airways. The complete disruption of the bronchial circulation during lung transplantation can cause a loss of epithelium integrity and associated mucociliary action, which may not fully recover despite development of collateral flow in the future [1, 2, 6, 8, 9]. Additional compromise of the anatomical barrier to infection is created by the potential suppression of the cough reflex caused by denervation of the allograft [4, 7]. Disruption of the normal lymphatic flow of...
the lung during transplantation also increases the risk of infections by creating edema and stasis of interstitial fluids [4, 7].

The incidence of allograft dysfunction due to both acute and chronic rejection in lung transplantation is among the highest in solid transplantation, requiring relatively high levels of immunosuppression targeting multiple lines of immune cells and their associated cytokine pathways.

The use of induction and high levels of maintenance of immunosuppression creates a significant risk for development of viral infection, with higher tacrolimus levels having been specifically associated with increased rates of CARV infections [2]. Prevention and suppression of infection by respiratory viruses involves the activities of cellular and antibody-mediated immunity, which are impaired by immunosuppression targeting adaptive T-cell-mediated processes. This point is highlighted by relatively weak antibody response to vaccines directed against certain respiratory viruses in recipients of solid organ transplantation [3, 10–13].

The transmission of donor-harbored infections at the time of transplantation is another factor that increases the likelihood of viral infection in the LTR [1, 4, 5]. With many viruses, the highest risk for development active disease exists in circumstances when a recipient with no prior exposure or established humoral immunity to a virus is “mismatched” with a donor whose tissues harbor the active infection or latent form of the virus. Viral infections that have previously been documented as originating from donor lung tissue include CMV, Epstein-Barr virus, varicella-zoster, adenovirus, influenza, hepatitis B and C, and human immunodeficiency virus, in addition to others [2, 4, 14, 15]. Therefore, at most centers, the evaluation of a donor for lung transplantation routinely includes serologic screening for common viruses, as well as bronchoscopic assessment with PCR analysis of BAL samples for common respiratory viruses [1, 2].

Reactivation of latent virus previously introduced to the LTR following induction and maintenance of immunosuppressive therapy is another risk factor for clinically significant viral infection [16–18]. For this reason the initial pretransplant candidate evaluation process includes a thorough screening for many of the same viruses listed above. In addition to helping to determine a patient’s candidacy for transplantation, this screening can help determine the need and duration of antiviral prophylaxis to specific viruses in the posttransplantation period [19, 20].

Infections with previously latent viruses in donor or recipient tissues are of significant concern early in the posttransplantation period. However, the period after several months posttransplantation represents its own risks for viral infection [2, 4, 5, 14, 15]. This phenomenon is related primarily to the return to community life by LTRs who have recovered from the initial surgical course and any subsequent physiologic or infectious insults. Evidence suggests LTRs who are greater than 1 year from surgery are five times more likely to present with CARV infections compared to those less than 1 year from transplantation [2, 14, 21].

**Changing Epidemiology of Viral Infections in Lung Transplantation**

Respiratory viruses and some members of the *Herpesviridae* family frequently cause clinically significant infections with potentially severe complications after solid organ transplantation (SOT).

Advancement in the field of diagnostic virology, primarily based on new molecular assays, has greatly improved the breadth and sensitivity of detection methods for viral infections. Multiplex PCR assays have now been available and FDA-approved for nearly a decade; they have provided a significantly larger number of small laboratories without expertise in viral culture techniques the opportunity to participate in real time diagnosis of a wide array of respiratory viral pathogens [22–24]. Furthermore, these new multiplex PCR-based assays are able to provide more rapid and sensitive identification of respiratory viruses than traditional viral culture and immunofluorescence testing [22, 25, 26].
Just in the last decade, several new viral respiratory tract pathogens have been identified, including human metapneumovirus (hMPV), human bocavirus (HBoV), new strains of human coronavirus (HCoV-NL63 and HCoV-HKU1), and new species of rhinovirus (HRV-C) [27, 28].

Respiratory and Other Viral Infections and Lung Allograft Dysfunction

The development of chronic lung allograft rejection (CLAD), encountered as bronchiolitis obliterans syndrome (BOS) or restrictive chronic lung allograft dysfunction (R-CLAD), continues to be the primary driver of mortality in LTR after the first 2 years following transplantation. Obliterative bronchiolitis, the hallmark of BOS, appears to be the pathologic end-stage of a process initially beginning with airway epithelial injury and leading to inflammatory reactions that promote airway obliteration. The inciting injury to the epithelium may be initiated as an exposure to toxic chemicals or drugs, infection including to viral agents, or an autoimmune process [3, 29, 30]. Airway inflammation and injury resulting from both the number and severity of episodes of acute rejection are also thought to play an important role in the development of CLAD [3, 33–35, 37, 39, 41, 42].

In cases where this relationship is seen, factors more likely to be associated with the development of graft dysfunction include respiratory virus infection involving the lower respiratory tract and infection with viruses known to cause more severe respiratory illness in general such as influenza and the paramyxoviruses [3, 33–35, 37, 39, 41].

The relationship between viral infection of the respiratory tract and development of allograft rejection would seem to be based on the similarity in pathogenesis of these processes. During the acute phase of a viral infection, as well as during the prolonged viral shedding often seen in the setting of lung transplantation, chemotactic cytokines released by injured parenchymal cells in the inflamed graft recruit alloreactive leukocytes. This process is further augmented by immune response specifically targeting the virus [44].

During this process, Th-1 and Th-2 CD4 T-cell subtypes and their associated cytokines interleukin (IL)-1, tumor necrosis factor, IL-6, and IL-8 are upregulated. The resulting alloreactive environment in the transplanted lung may lead to immune-mediated injury to the airway and subsequent rejection and graft dysfunction [45–51].

In recent lung transplant literature, the activity of the CXCR3 receptor expressed on the surface of activated lymphocytes provides further evidence supporting the role of viral infection in the development of lymphocyte-mediated allograft dysfunction [52, 53]. The CXCR3 receptor and its ligands, CXCL9-11, have roles both in the immune response to viruses and in the development of BOS [54–56].
CXCR3 ligand are increased and associated with larger decline in FEV₁ at 6 months [52].

In the case of CMV specifically, which is not a member of the CARV group, the interplay of viral-associated changes and host immune factors forms a pathophysiologic relationship that promotes development of allograft dysfunction. Here the cytokine cascades induced by the activity of CMV infection, as well as cytokines involved in the pathophysiology of rejection, promote the progression of one another [57–60]. The release of tumor necrosis factor-alpha during allograft rejection, which acts as a key reactivation signal for latent CMV, facilitates viral replication and progression to active infection. Meanwhile the activity of CMV within the vascular endothelium and smooth muscle induces the upregulation of adhesion molecules which promote further proliferation and activity of inflammatory cells in the graft, leading to development of rejection. CMV has been thought to play an additional role in the development of rejection by the process of molecular mimicry, where the immune response against viral antigens leads to the production of anti-endothelial antibodies within the graft [2, 42, 57, 58, 60, 61].

Respiratory Viruses and Viral Infections Relevant to Lung Transplantation

Community-Acquired Respiratory Viruses (CARVs)

CARVs represent a diverse group of human pathogenic viruses, which belong to several distinct families. These include the Paramyxoviridae (RSV, hMPV, and PIV), Orthomyxoviridae (influenza A and B), Picornaviridae (rhinovirus and enteroviruses), Adenoviridae (adenovirus), and Coronaviridae (coronaviruses) [27, 28].

These viruses represent the most common causes of human respiratory infections and are most commonly acquired from contact with infected individuals or secretions left in the environment by an infected person [62–64]. Modes of transmission include contact with secretions followed by autoinoculation of mucosal membranes versus direct inoculation large droplets or aerosols.

Infection patterns for some of these organisms follow typical seasonal or temporal patterns and in these cases tend to mirror patterns in the general community. Healthcare-associated infections can also occur, even exhibiting cases of outbreaks within hospitals [65].

CARV infections can lead to serious complications in those with predisposing factors such as immunosuppression and altered pulmonary anatomical defense mechanisms, with LTR at particularly high risk of developing severe infections. Infections of the respiratory tract by CARVS in LTR can be further complicated by the occurrence of secondary bacterial infections and increased incidence of associated acute and chronic rejection [4, 21, 42, 64, 66, 67].

Picornaviruses, primarily RhV, are the most common viruses found in nasopharyngeal and BAL samples collected from LTR bit at routine screening and healthcare visits specifically for respiratory and infectious symptoms [14, 42, 67, 68]. Common CARVs and other RhV are much more likely to be isolated during emergency visits than routine screening, suggesting a higher incidence of symptomatic infection [14]. In general the LTR population can have as high as a 10% incidence of positive tests for CARV infection at surveillance screening without symptoms, with nearly double this rate when tested while presenting with symptoms of an acute respiratory illness [4, 14, 69].

The spectrum of disease severity for CARV infection in LTR varies significantly and does so depending on the specific infectious agent. RhV infections which are the most common of CARVs can often present with limited symptoms or be found on asymptomatic screening in one third of cases [14]. The most common symptoms of RhV infection include rhinorrhea and nasal congestion, with fevers and myalgias being relatively uncommon. Meanwhile, infections with influenza and paramyxoviruses (RSV and PIV) are almost always associated with symptoms and much more likely to be febrile illnesses [14, 67, 69].
Lower respiratory tract involvement with radiographic manifestation is typically rare except in the case of influenza. Infections with influenza and paramyxoviruses are also more than twice as likely to result in hospitalization compared with RhV and coronavirus, with nearly 50% of cases requiring admission [14, 21, 70].

In nearly all cases of symptomatic infection with CARVs, lower FEV₁ and FVC can be seen when compared to preinfection values for patients [14].

**Respiratory Syncytial Virus (RSV)**

RSV is an almost universally common respiratory tract infection of early childhood. It carries an incomplete pattern of natural immunity and frequent reinfections [45, 71]. It is the most characteristic virus of the Paramyxoviridae. RSV is among the most commonly isolated CRVs and clinically ranges from mild upper respiratory infection symptoms such as rhinorrhea and cough to life-threatening lower respiratory tract infections with bronchiolitis and pneumonia similar to influenza. Risk factors for more severe disease include higher levels of immunosuppression, infection immediately following transplantation, and pre-existing pulmonary pathology. In LTR, RSV infection can cause significant morbidity and can be associated with acute and chronic graft dysfunction [72, 73]. RSV has been shown to significantly increase the risk of graft dysfunction, with as much as a mean FEV₁ decline of 30% in some series and associated mortality ranging from 10 to 15% [74–76].

Reverse transcription-polymerase chain reaction (RT-PCR)-based assays are the current mainstay of diagnosis with excellent sensitivity in symptomatic patients, while fluorescent antibody and serologic testing as well as viral culture can also be used to diagnose acute infection [76].

In the normal host, RSV infection primarily affects airway epithelial cells. The subsequent immune response, mediated in part by the IL-2-mediated T-helper 1 (Th1) activity, can clear the infection and prevent a prolonged inflammatory response leading to reactive airways disease [69, 77–80]. Th1 deficiency, meanwhile, can be associated with viral persistence and chronic airway inflammation, with a Th2-driven interleukin-10-associated response [81]. Suppression of the IL-2 pathway in LTR and the associated alterations in mucosal immunity may influence the pathogenesis of RSV infection in LTR and subsequent allograft dysfunction.

**Prophylaxis and Treatment**

Currently, there is no vaccine or antiviral prophylactic regimen for RSV, but there are multiple clinical trials assessing the effectiveness of innovative RSV vaccines. Pavilizumab is recommended for prophylaxis in children meeting treatment criteria, but the use of this medication for the prevention of RSV in older transplant recipients is not recommended [82].

There are limited data regarding the role of antiviral therapy to treat RSV in lung transplant recipients. Currently, the drug of choice is ribavirin with or without corticosteroids, which can be administered intravenous, orally, or inhaled (Table 15.1) [82, 83, 85–87]. Treatment decisions are commonly dependent on the severity of disease, and inhaled ribavirin is most often the route of choice for severe RSV infections. Inhaled ribavirin has many drawbacks: administration requires a hospital admission and an extended inhalation interval, and it can be teratogenic to women of child-bearing age. Because of these factors of the medication, appropriate precautions should be taken [82]. Intravenous ribavirin has reported success, although it is only available through compassionate use in the United States.

**Table 15.1 Ribavirin treatment regimens**

| Dosage form | Regimen | Duration |
|-------------|---------|----------|
| Inhaled ribavirin | 6 gm over 12–18 h | 3–7 days |
| IV ribavirin [83, 84] | Day 1: 33 mg/kg in three divided doses (q8h) Maintenance: 20 mg/kg/day in three divided doses every 8 h | 7 days + negative swab |
| PO ribavirin [84, 85] | 400 mg three times daily ± loading dose Or 20 mg/kg/day divided every 8 h | 5–10 days |

Data from References [83–86]
Adjunctive therapy using palivizumab and intravenous immunoglobulin has been used, with little published efficacy [82, 88]. Lastly, pre-satovir and ALN-RSV01 are medications undergoing phase II clinical trials to assess the efficacy of these novel antiviral agents for the treatment of RSV infections in lung transplant patients [89].

**Parainfluenza Virus (PIV)**

The PIV family includes four major serotypes that have been found to cause human disease, with serotype 3 most commonly isolated from LTRs. Incidence of respiratory infection with parainfluenza virus ranges from 2 to 10% of all LTRs. As a community-acquired infection, the majority of cases occur more than 1 year following transplantation, with seasonal peaks in the warmer months of spring and summer [69, 90]. Parainfluenza virus infections have been associated with high rates acute cellular rejection, up to 82% in one series. Furthermore in this series, a significant portion, nearly one third of cases, progressed to develop BOS [90].

**Prophylaxis and Treatment**

There are no known vaccines or prophylactic antiviral medications known to prevent parainfluenza. Currently, there are no proven treatments for parainfluenza viral infections. Ribavirin, steroids, and IVIG have been used to treat parainfluenza infections in transplant recipients but have not been proven to provide benefit [91]. DAS181, a novel sialidase fusion protein, has been used through compassionate use and is currently in phase II trials for treatment of parainfluenza in immunocompromised patients [92, 93].

**Human Metapneumovirus (hMPV)**

hMPV is a relatively new addition to the paramyxovirus family. hMPV presents with a clinical spectrum of disease similar to RSV, albeit typically less severe. Disease severity can range from asymptomatic infection to severe lower respiratory tract infection [94, 95]. Current data do not support an association with hMPV infection and the development of persistent allograft dysfunction as is the case with RSV [96]. However, evidence of acute decline in lung function following hMPV infection does exist [69, 74, 75].

**Influenza A and B Virus**

Influenza A and B viruses are associated with seasonal infections, most common in the winter months and accounting for up to 5% of viral infections in LTRs [97]. Compared to normal hosts, where influenza infection is typically a self-limited upper respiratory syndrome with myalgias and fever, the risk of lower respiratory tract involvement is higher for LTRs and immunocompromised populations in general [35, 43]. Consequently, the Centers for Disease Control recommend annual influenza vaccination and chemoprophylaxis for the immunocompromised during community outbreaks [98].

In some series a majority of LTR patients with active influenza had concomitant acute allograft rejection, and seasonal increases in BOS have been suggested to have association with influenza outbreaks [36, 41, 99, 100]. Despite this, unlike paramyxovirus infections, serious influenza disease does not appear to be very common in LTR [72]. Rapid diagnostic methods using antigen-based assays or PCR amplification of target nucleic acid sequences can be performed on nasopharyngeal swabs or BAL samples.

**Prophylaxis**

The immunogenicity of the influenza vaccine in lung transplant recipients is unknown [82]. Even so, seasonal influenza vaccine is recommended for transplant patients [101]. Along with immunizing transplant patients themselves, herd immunity is a very important strategy when it comes to posttransplant patient care. Therefore, it is essential to ensure all close contacts of lung transplant recipients are also vaccinated. There are two types of influenza vaccines available: the intranasal live attenuated influenza vaccine and the intramuscular inactivated vaccine. Live attenuated vaccines are contraindicated in
transplant recipients; therefore, the inactivated vaccine is to be administered. Due to the intensity of immunosuppression directly posttransplant and concern of decreased immunogenicity, vaccinations are often withheld directly after transplantation. According to the American Society of Transplantation, a reasonable time frame is to wait at least 3 months after transplant before influenza vaccine administration [82].

Postexposure prophylaxis with oseltamivir or zanamivir may be indicated in transplant recipients exposed to influenza, primarily if it is an exposure of someone living in their household [82]. Prophylaxis should be initiated if patient presents within 48 h of exposure for oseltamivir and 36 h of exposure for zanamivir [102, 103]. See Table 15.2 for prophylaxis dosing and duration.

**Treatment**

There are two classes of antivirals that have been used to treat influenza: the M2 inhibitors (amantadine and rimantadine) and neuraminidase inhibitors (oseltamivir, zanamivir, and peramivir). The neuraminidase inhibitors are preferred agents to treat influenza [82]. M2 inhibitors are no longer recommended due to increased resistance and inactivity to influenza A and B, respectively [82]. Oseltamivir is commercially available as a capsule and suspension; zanamivir is administered as an inhalation and peramivir as an infusion [102–104]. Currently, the IV formulation of zanamivir and oseltamivir are only available as an investigational use, and not commercially available. Oseltamivir is the most used antiviral to treat influenza in the lung transplant population; zanamivir and peramivir lack data for severe disease and for treatment of hospitalized patients [101, 105]. The usual duration of therapy for influenza A or B treatment is 5 days, although immunosuppressed patients, including lung transplant recipients, may have prolonged viral replication and also have an increased risk of developing antiviral resistance; therefore, longer duration of therapy can be considered [82, 105]. Dosing and duration of therapy is presented in Table 15.2.

**Rhinoviruses (RhV)**

RhVs are the most common cause of colds in adults and are members of the Picornaviridae family [66]. Much like in the general population, RhVs are increasingly recognized as the most common cause of respiratory viral illness in the LTR [66, 106–111]. In addition, as many as 50% of PCR-documented cases of RhV infections in transplant recipients have few to no symptoms at the time of surveillance testing [106, 108, 112]. The typical clinical presentation involves an afebrile upper respiratory illness with rhinorrhea and sinus congestion. It is sometimes associated with sore throat and cough. Coinfections with

---

**Table 15.2** Dosing of anti-influenza medications

|                | CrCl (mL/min) | Treatment                          | Duration | Prophylaxis             | Duration |
|----------------|--------------|------------------------------------|----------|-------------------------|----------|
| Oseltamivir    | ≥60          | 75 mg twice daily                  | ≥5 days  | 75 mg once daily        | 7–10 days|
|                | 30–60        | 30 mg twice daily                  |          | 30 mg once daily        |          |
|                | 10–30        | 30 mg once daily                   |          | 30 mg every other day   |          |
|                | HD/CrCl<10   | 30 mg after each HD session        | 5 days   | 30 mg after every other HD cycle |          |
| Zanamivir      | N/A          | Two inhalations (10 mg) twice daily| ≥5 days  | Two inhalations (10 mg) once daily | 10 days  |
| Peramivir (IV) | ≥ 50         | 600 mg                             | Single dose | N/A                |          |
|                | 30–49        | 200 mg                             |          | N/A                    |          |
|                | 10–29        | 100 mg                             |          | N/A                    |          |
|                | < 10/HD      | Dose after dialysis, adjusted based on creatinine clearance | | | |

Data from References [102–105]
other pathogens complicate many cases of RhV infection in LTR and may contribute significantly to the relatively high morbidity and mortality rates observed [110].

The incidence of RhV-associated lower respiratory tract infection in LTR has been documented in contrast to typically mild and self-limited disease in the general population. These events are associated with risk of both acute and chronic rejection and increased mortality [106, 110].

There are currently no specific prophylactic or treatment options available for RhV.

**Adenovirus**

Adenovirus is a non-enveloped DNA virus ubiquitous in the community. Adenovirus causes a primary infection in all individuals typically in the first few years of life and counts for about 10% of all childhood respiratory illness. From there the virus may remain in lymphoepithelial tissues in latent form and subsequently create disease by reactivation [70, 113].

The mode of transmission of adenovirus in general involves inhalation of aerosolized droplets, direct contact with conjunctival secretions, feco-oral contamination, or contact with infected blood [66]. In the immunocompromised, speculation exists regarding adenovirus disease as either a primary infection from the environment or the result of transmission from the donor tissue and reactivation of previously latent virus epithelia of the pharynx, intestinal tract, and urinary tract [13, 114, 115].

In the immune competent host, symptoms associated with infection are usually self-limited, including cough, pharyngitis, keratoconjunctivitis, gastroenteritis, and fevers.

Disease in the immunocompromised, including LTR, has a wide range of severity. Although asymptomatic infection is reported, severe disease with significant morbidity and mortality can also occur. Infection sites in the immunocompromised are typically comprised of the urinary tract, gastrointestinal tract, lung, and liver [116]. More severe disease and poorer outcomes can be predicted based on higher number of affected sites and organ systems involved, as well as pathologically determined invasive disease [116–118].

The more feared complications of adenovirus infection for the recipients of solid organ transplants include pneumonia and hepatitis, with mortality rates of up to 50% documented [70].

Severe pulmonary infections have specifically been documented in LTR, with many of these cases progressing to respiratory failure with high mortality rates. In these instances, pathologic assessments at autopsy have revealed necrotizing hemorrhagic pneumonia with diffuse alveolar damage, as well as invasive disease represented by basophilic inclusions within bronchial epithelial cell consistent with adenovirus infection [114]. These severe infections have been documented to occur both in the first few weeks following transplantation and less frequently years after returning to the community [114, 119].

**Prophylaxis and Treatment**

There are no vaccines or established chemoprophylaxis to prevent adenovirus in solid organ transplant recipients.

Currently, there are no randomized controlled trials regarding the treatment of severe adenovirus infections. The current preferred therapy for most centers is minimization of immunosuppression. If an antiviral is needed cidofovir can be considered [120]. This drug should be utilized with caution; cidofovir administration is associated with significant adverse reactions, primarily neutropenia and nephrotoxicity, both of which are pronounced with lung transplant [120, 121]. In order to mitigate nephrotoxicity caused by cidofovir, probenacid and hydration should be added to the regimen [121]. Probenacid is administered 3 h before, 3 h after, and 8 h after cidofovir, along with hydration with normal saline [120, 121]. As adjunct to reduced immunosuppression with or without cidofovir, immunoglobulin may be considered, primarily in patients with hypogammaglobulinemia [120], although the benefits of IVIG in the setting of adenovirus infection with or without hypogammaglobulinemia are still not clear. In the future, brincidofovir (CMX001), a
lipid conjugate of cidofovir which is currently in clinical trials, may be a viable option. Benefits of this dosage form may include an oral formulation, higher potency, and less nephrotoxicity.

Coronaviruses

Coronaviruses are a frequent cause of the common cold with currently an unclear role in infections affecting LTR [14, 21, 68]. New sensitive molecular assays for detection of coronavirus infection can help to detect this virus, which can range from simple upper respiratory illness to severe lower respiratory tract infections [122]. Severe infections in the immunocompromised can present as pneumonia and bronchiolitis [123, 124].

Similar to RhV infections, no current pharmacologic options for prophylaxis or treatment are available.

Human Bocavirus (HBoV)

HBoV, a recently identified member of the Parvoviridae family, can cause respiratory disease in humans with typically seasonal pattern in winter [125, 126]. Although a great deal of data regarding infections in the immunocompromised has not yet been compiled, case reports have documented severe respiratory and disseminated infections in the setting of lung transplantation [127].

β-Herpesviruses

The Herpesviridae are a heterogeneous family of morphologically similar double-stranded DNA viruses that can infect humans and other animals. Humans act as primary hosts for eight members of this virus family and are typically transmitted through direct person-to-person contact.

Cytomegalovirus (CMV)

CMV is the most common and important among the opportunistic infections that complicate lung transplantation. Its association to morbidity and mortality posttransplant has been well documented and increasingly shown to be mediated by elevated risk of acute and chronic allograft dysfunction [2, 32, 128–131].

CMV exposure and seropositivity are ubiquitous in the general population, ranging from 30 to 97% [59]. Exposure to and infection with the virus confer a life-long carrier status with risk of future reactivation in the setting of a compromised immune system [2, 69, 132]. The overall incidence of CMV infection in LTR has been reported as the highest among all solid organ transplants, with figures ranging from 30 to 86% of patients, in part due to the relatively higher-level immunosuppression required in the post-lung transplantation setting [57, 59]. The high incidence rates and associated complications of CMV infection exact a high price on the LTR population, with mortality rates reported at 2–12% [2, 57, 69].

Unlike community-acquired infections, the primary risk factor development of CMV infection appears to be a mismatch between the serostatus of donor and recipient [57, 59, 131]. The highest risk category is that of a seropositive donor with seronegative recipient, in which case the transplant recipient who lacks previously formulated immunity to CMV receives exposure to the virus harbored within the allograft at a time when immunosuppression is at its most aggressive [59]. The intensity of the immunosuppression regimen, both at induction and maintenance, is also an important risk factor for CMV infection, as are host factors such as age medical comorbidities [57, 59]. Other modes of infection include transfusion of blood products from a seropositive donor and reactivation of latent infection in a seropositive LTR.

Clinical Manifestations

CMV infection and disease are distinct clinical entities. Replication of CMV with or without symptoms is regarded as infection, while the presence of symptoms or physiologic changes attributable to CMV is required to meet a definition of disease. The hallmarks of CMV disease include fevers and malaise, myalgias and
arthralgias, leukopenia and thrombocytopenia, as well as tissue invasive manifestations [20, 59].

Tissue invasive disease most commonly manifests as a pneumonitis. This syndrome can present with subtle fevers, nonproductive cough, and dyspnea associated with decline in pulmonary function tests. Other manifestations of tissue invasive disease include incidences of hepatitis associated with abnormal liver function tests, and gastroenteritis and colitis typically presenting with nausea, vomiting, and diarrhea [20].

**Diagnosis**

Quantitative nucleic acid-based amplification assays utilizing polymerase chain reaction (PCR) technology for the identification of viremia have largely replaced previously used methods of diagnosis relying on antigen detection for viral particles. Monitoring and diagnosis of CMV infection is now used in the overwhelming majority of transplant center [133]. Despite this, there is no current consensus on threshold values of CMV viral load considered to be an indicator of infection. Viral culture performed on blood, urine, and BAL samples is no longer routinely recommended for detection of CMV [42].

The presence of cell-mediated immunity to CMV, as determined by quantiferon-CMV assay measuring the presence of a CD8 T-cell response to the virus, holds promise as a marker to determine risk of CMV disease. Patients with positive CMV interferon-gamma release assays have been shown to more frequently clear viremia without progression to clinical disease, while those with negative assays suffer higher rates of late onset CMV disease after discontinuation of prophylactic therapy [134, 135].

**Treatment General**

Intravenous ganciclovir has historically been the treatment of choice for the treatment of CMV [136]. The IV formulation is still the drug of choice for severe life-threatening disease and in patients who have severe diarrhea or cannot tolerate medications by mouth [137]. In 2007, the Victor Study group concluded that oral valganciclovir is also a treatment option in select solid organ transplant recipients with mild to moderate disease [138], although it should be noted that less than 10% of the patients in the Victor Study were lung transplant recipients, and these patients did not have severe disease [138]. Whether using intravenous ganciclovir or oral valganciclovir treatment should be continued for 14–21 days plus viral clearance [136]. If virus is not cleared after 21 days, there is a high risk for recurrent disease; therefore, longer duration may be necessary if resolution of viremia is not accomplished [136–138]. Table 15.3 outlines dosing guidelines adjusted for renal function for both ganciclovir and valganciclovir.

**Prophylaxis**

Chemoprophylaxis for CMV should be started as soon as possible, and always within 10 days after transplantation for those at risk for CMV [136]. Recommendations for prophylaxis of CMV disease in lung transplant recipients are based on donor and recipient IGG serostatus (Table 15.4). For patients at the highest risk for developing CMV disease, donor IGG positive and recipient IGG negative (D+/R−), prophylaxis with IV ganciclovir, valganciclovir, or a combination of both is recommended [136]. The duration of prophylaxis varies, but at least 12 months of prophylaxis is recommended, with some centers extending prophylaxis beyond 12 months [136, 142]. As adjunct to chemoprophylaxis, CMV immune globulin can also be considered for the D+/R− high-risk group of patients [136]. For moderate-risk recipient IGG seropositive recipients, IV ganciclovir or valganciclovir is recommended for 6–12 months [136, 142, 143]. For low-risk donor and recipient IGG seronegative negative patients, no CMV-specific prophylaxis is necessary [136, 142]. HSV prophylaxis with acyclovir is still indicated, but neither ganciclovir nor valganciclovir is required [35, 142, 144] (Table 15.4). Preemptive therapy, i.e., withholding valganciclovir or IV ganciclovir prophylaxis and monitoring patients on a weekly basis for CMV viremia then treating to prevent disease progression, is generally not recommended in lung transplant recipients [136].
| Estimated CrCl | Valganciclovir          | Ganciclovir          |
|----------------|-------------------------|----------------------|
|                | Prophylaxis/maintenance | Treatment/induction  | Estimated CrCl | Prophylaxis/maintenance | Treatment/induction  |
| CrCl ≥60 mL/min| 900 mg daily            | 900 mg twice daily   | CrCl ≥70 mL/min| 5 mg/kg daily            | 5 mg/kg twice daily |
| CrCl 40–59 mL/min| 450 mg daily           | 450 mg twice daily   | CrCl 50–69 mL/min| 2.5 mg/kg daily          | 2.5 mg/kg twice daily |
| CrCl 25–39 mL/min| 450 mg every other day | 450 mg daily         | CrCl 25–49 mL/min| 1.25 mg/kg daily         | 2.5 mg/kg daily     |
| CrCl 10–24 mL/min| 450 mg twice weekly    | 450 mg every other day| CrCl 10–24 mL/min| 0.625 mg/kg daily        | 1.25 mg/kg daily     |
| CrCl <10 mL/min | Use not recommended consider ganciclovir |                          | CrCl <10 mL/min | 0.625 mg/kg three times weekly following dialysis | 1.25 mg/kg three times weekly following dialysis |
| Alternative dosing valganciclovir in dialysis | Solution 100 mg three times weekly following dialysis | Solution 200 mg three times weekly following dialysis |

Data from References [139–141]
Resistance
An emerging concern is the management of ganciclovir-resistant CMV disease. Ganciclovir resistance is associated with high morbidity and mortality, and there are few options when it comes to treatment [145]. Current drugs of choice are either foscarnet or cidofovir, both of which are highly toxic and require extended hospitalizations when initiating therapy. Resistance is usually due to a mutation of the UL97 gene and less commonly the UL54 gene [136, 145]. The UL97 mutation does not confer resistance to cidofovir or foscarnet, but the UL54 mutation may confer resistance to all three medications and is therefore more difficult to treat [136, 145]. Many times as adjunct to cidofovir or foscarnet transplant, centers consider discontinuation of the current antimetabolite and initiating leflunomide, which has both antiviral and antimetabolite properties [146, 147]. Future options for treatment of CMV include maribavir and brincidofovir (CMX001), both of which are currently in clinical trials and not available for use [148, 149]. No matter the situation, treatment of ganciclovir-resistant CMV should be undertaken with caution and on a case by case basis.

Epstein-Barr Virus (EBV)
EBV, an oncogenic virus, holds a strong association for the development of post-lymphoproliferative disease (PTLD). Encompassing a heterogeneous group of lymphoproliferative disorders, PTLD ranges from a reactive polyclonal lymphoid hyperplasia to aggressive non-Hodgkin’s lymphomas. A deficient EBV-specific cellular immune response caused by immunosuppressant regimens is considered to be at the etiology of PTLD [68, 150]. In the setting of lung transplantation, the incidence of PTLD has been noted to range from 1 to 20%, with intense prolonged immunosuppression and EBV mismatch (EBV positive donor and EBV negative recipient) considered major risk factors [150–152]. In the setting of EBV mismatch, monitoring of viral load can be clinically useful as a continuous increase of EBV load may indicate pending development of PTLD [153].

Prophylaxis and Prevention
Overall immunosuppression plays a vital role in EBV and PTLD occurrence [154]. The use of lymphocyte-depleting therapy has been linked to increased PTLD cases [154]. This should be considered with discussing the use of lymphocyte-depleting induction and treatment approaches in order to prevent rejection and minimize the risk of PTLD [154]. Both acyclovir and ganciclovir have in vitro activity against EBV lytic replication and have been used as prophylaxis, although efficacy is not proven [154].

Another approach is monitoring of EBV viral load with serial PCRs during posttransplant follow up. This allows centers to preemptively add chemoprophylaxis, decrease immunosuppression, and trend the viral load. As with other prophylactic strategies, the efficacy of EBV monitoring and preemptive intervention to decreases the occurrence of PTLD posttransplant has is not established.
Treatment
Minimization of immunosuppression is a mainstay in management of EBV and PTLD. With reduced immunosuppression, the reconstituted cytotoxic T-Cell population is thought to control the EBV infected B-cell population [154]. The addition of antiviral medication in combination to reduced immunosuppression for patients with PTLD is controversial. This is primarily due to the majority of EBV within a PTLD mass not undergoing lytic infection; therefore, the utility of antiviral therapy is not well defined [154]. IVIG has also been considered as an adjunctive therapy to the treatment regimen, although the benefit of the addition of IVIG is not established.

Anti-CD20 treatment with rituximab with or without traditional chemotherapy is an option depending on severity of the disease and patients response to reduced immunosuppression [154]. Usual regimens are those similar to B-cell lymphoma, often requiring CHOP [154]. Even with treatment options, PTLD in lung transplant recipients remains a high cause of morbidity and mortality. Recently a single center reported approximately 50% of patients treated with a rituximab-based therapy had full remission of disease and 22% with no response to treatment and a 5-year survival of only 29% after PTLD diagnosis [155].

Due to the complexity of the transplant and severity of PTLD, a multidisciplinary approach is often beneficial. Patients, transplant care providers, along with a cancer treatment center can devise a plan that would best fit each individual patient and maximize outcome and quality of life.

Herpes Simplex Virus (HSV) 1 and 2 and Varicella-Zoster Virus (VZV)

HSV and VZV are members of the Alphaherpesvirinae which previously represented opportunistic infectious agents in first week post-lung transplantation. Infection with HSV in particular was a cause of severe pneumonitis in up to 10% LTR and associated with high mortality rates [4, 68]. However, severe HSV infection has since become a relatively rare complication with improved antiviral prophylaxis in the posttransplant setting.

Herpes zoster, caused by the reactivations of dormant VZV infection, presents with painful vesicular dermatomal skin lesions. Development of zoster in LTR bears a cumulative probability of approximately 20% after 5 years posttransplantation, with over 5% of cases progressing to disseminated cutaneous infection. Following occurrence of herpes zoster, the post-herpetic neuralgia syndrome can be observed in nearly one of five of those effected [151].

Prophylaxis
Prior to listing, transplant candidates should be evaluated for varicella seropositivity [156]. Seronegative patients are commonly considered for the varicella vaccine, administered least 14 days prior to transplantation [156]. The varicella vaccine is a live-attenuated vaccine and should not be administered after transplantation; therefore, every effort should be made to vaccinate appropriate patients prior to transplantation [156].

All lung transplant recipients should receive prophylaxis for herpes viruses directly after transplantation [156, 157]. Most patients will be receiving prophylaxis with valganciclovir for CMV; this is sufficient herpes virus prophylaxis [156, 157]. For patients who do not require CMV prophylaxis (donor and recipient are seronegative for CMV), acyclovir or valacyclovir is the drug of choice for prophylaxis [156, 157], although famciclovir is also acceptable (Table 15.5).

Treatment
Treatment as an outpatient with oral antivirals is appropriate for mucocutaneous and mild to moderate disease in lung transplant recipients. Patients with moderate to severe disease who are hospitalized require more aggressive therapy [156, 157]. For these transplant recipients, primarily those diagnosed with disseminated or
CNS disease, intravenous acyclovir is the drug of choice (Table 15.5) [156, 157].

Duration of therapy ranges from 7 to 21 days depending on the severity of disease [156, 157]. For localized herpes zoster infections, therapy should be continued for at least 7 days AND until the lesions are crusted over [156]. It should be noted that a delay in lesion crusting is commonly seen in transplant recipients, which often extends the duration of therapy. In general, duration of treatment for mild to moderate HSV and VZV disease is recommended to for 7–14 days, and 21 days in severe and central nervous system infections [156, 157].

**Human Herpes Virus (HHV) 6 and 7**

HHV-6 and HHV-7 are lymphotropic viruses belonging to the same subfamily as CMV. They can cause primary infections during early childhood. Patients who have undergone solid organ transplantation have been noted to suffer reactivation of disease typically early in the posttransplantation period [162].

The clinical syndrome associated with HHV-6 can consist of skin rashes, hepatitis, bone marrow suppression, pneumonitis, and encephalopathy, although severity of infection varies and the majority of cases are thought to be asymptomatic [68, 162].

The clinical impact of HHV-7 is less well characterized.

**Human Herpes Virus (HHV) 8**

HHV-8 is the virus associated with the development of Kaposi’s sarcoma (KS), which is a well-characterized entity following SOT in heart, renal, and liver transplant recipients. The incidence of KS after transplantation in the United States is approximately 0.4%, with the majority of cases occurring in renal transplant recipients. In about 60% of cases, KS lesions are confined to skin and mucosa of the oropharynx, while the remainder can exhibit involvement of internal organs and lymph nodes [163]. In the last few decades, a mounting number of cases of KS in LTR have brought recognition to HHV 8 as an important pathogen in the setting of lung transplantation [163, 164]. KS, considered a rare malignancy in LTR, can manifest with involvement of the allograft as bronchial and pleural disease, as well as cutaneous lesions or involvement of other viscera such as the gastric or intestinal tracts [163–166]. It should be considered in patients with characteristic skin lesions and pulmonary disease, including hemorrhagic pleural effusions that are typically rich in HHV-8 viral particles and DNA when tested [166]. Furthermore, an association between increasing HHV-8 viremia and progression of pulmonary KS has been previously described [163].

Although data on the management of this rare entity in LTR are limited, most cases appear to have full or partial response to reduction in immunosuppression, with small case series showing response to therapy with sirolimus.
Other therapies traditionally used in the treatment of KS include conventional chemotherapies with bleomycin, vincristine, and doxorubicin in addition to radiation, although there are no data regarding these therapeutic modalities in the setting of lung transplantation. 

HHV-8 is susceptible in vitro to the anti-Herpesviridae agents cidofovir, foscarnet, and ganciclovir, with data from the management of KS in the setting of HIV suggesting a reduced risk of developing KS [167–169]. However, data on the use of these agents in the management of KS following SOT are again limited.

### Other Viruses

Several other viral infections have been documented to create complications in the course of lung transplantation. Although largely out of the scope of this chapter, a few examples are briefly discussed below.

#### BK Virus

BK virus is a member of the human polyomavirus family, almost universally infecting healthy adults with seroprevalence in up to 100%. Data from kidney transplant recipients provide the largest source of information regarding clinically infection with BK virus, where reactivation of BK virus occurs in up to 45% and may cause parenchymal and obstructive renal allograft disease. In the setting of lung transplantation, only rare cases of BK virus-associated nephropathy of native kidneys have been reported [170–172].

#### Prevention and Treatment

Standard of prevention and treatment of BK virus in lung transplantation is not well established. Although BK virus may be detected in the urine of over 25% of lung transplants, viuria has not shown to have an effect on renal function [170, 173, 174]. Therefore, decreasing immunosuppression or the use of other treatment modalities, such as leflunomide for BK virus in lung transplantation, is not established as a standard of care.

### Parvovirus B19

Parvovirus B19 can cause pure red cell aplasia, more commonly seen in renal transplant recipients. It has been shown to occur as a very rare complication after lung transplantation, in isolated case reports [68, 175]. Despite the relative lack of data in the literature on this subject, the ubiquity of parvovirus exposure in the community warrants investigation of this possibility in cases of unexplained isolated anemia in LTRs [176, 177].

### Summary

Chronic lung allograft dysfunction (CLAD) continues to be the major causes of morbidity and mortality after lung transplantation. Viruses, especially the community respiratory viruses (CRV), are common and have also been a major source of morbidity in lung transplant recipients. An important and newly intense area of focus for research has been the interface between respiratory viruses, the respiratory virome, and chronic rejection. With improved techniques to study the pathogenesis of all types of chronic rejection as well as recent advances in metagenomics, we are no doubt in a place now when we can move forward in not only understanding the relationship between viruses and lung allograft rejection but also being able to work toward a solution.

### References

1. Kotloff RM, Thabut G. Lung transplantation. Am J Respir Crit Care Med. 2011;184(2):159–71.
2. Burguete SR, Maselli DJ, Fernandez JF, Levine SM. Lung transplant infection. Respirology. 2013;18(1):22–38.
3. Vilchez RA, Dauber J, Kusne S. Infectious etiology of bronchiolitis obliterans: the respiratory viruses connection—myth or reality? Am J Transplant. 2003;3(3):245–9.
4. Speich R, van der Bij W. Epidemiology and management of infections after lung transplantation. Clin Infect Dis. 2001;33(Suppl 1):S58–65.
5. Witt CA, Meyers BF, Hachem RR. Pulmonary infections following lung transplantation. Thorac Surg Clin. 2012;22(3):403–12.
6. Norgaard MA, Andersen CB, Pettersson G. Airway epithelium of transplanted lungs with and without direct bronchial artery revascularization. Eur J Cardiothorac Surg. 1999;15(1):37–44.
7. Jordan S, Mitchell JA, Quinlan GJ, Goldstraw P, Evans TW. The pathogenesis of lung injury following pulmonary resection. Eur Respir J. 2000;15(4):790–9.
8. Verleden GM, Vos R, van Raemdonck D, Vanaukenaerde B. Pulmonary infection defense after lung transplantation: does airway ischemia play a role? Curr Opin Organ Transplant. 2010;15(5):568–71.
9. Gade J, Qvortrup K, Andersen CB, Thorsen S, Svendsen UG, Olsen PS. Bronchial arterial vascularization. An experimental study in pigs. Scand Cardiovasc J. 2001;35(3):212–20.
10. Blumberg EA, Albano C, Pruett T, Isaacs R, Fitzpatrick J, Bergin J, Crump C, Hayden FG. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis. 1996;22(2):295–302.
11. Fraund S, Wagner D, Pethig K, Drescher J, Girgsdies OE, Haverich A. Influenza vaccination in heart transplant recipients. J Heart Lung Transplant. 1999;18(3):220–5.
12. Kumar SS, Ventura AK, VanderWerf B. Influenza vaccination in renal transplant recipients. JAMA. 1978;239(9):840–2.
13. Humar A, Kumar D, Mazzulli T, Razonable RR, Moussa G, Pavy CV, Covington E, Alecock E, Pescevitz MD, PV16000 Study Group. A surveillance study of adenovirus infection in adult solid organ transplant recipients. Am J Transplant. 2005;5(10):2555–9.
14. Bridevaux PO, Aubert JD, Soccal PM, Mazza-Stalder J, Berutto C, Rochat T, Turin L, Van Belle S, Nicod L, Meylan P, Wagner G, Kaiser L. Incidence and outcomes of respiratory viral infections in lung transplant recipients: a prospective study. Thorax. 2014;69(1):32–8.
15. Sims KD, Blumberg EA. Common infections in the lung transplant recipient. Clin Chest Med. 2011;32(2):327–41.
16. Allen U, et al. Discipline of transplant infectious diseases (ID). Foreword. Am J Transplant. 2009;9(Suppl 4):S1–2.
17. Smyth RL, Higenbottam TW, Scott JP, Wreghitt TG, Stewart S, Clelland CA, McGoldrick JP, Wallwork J. Herpes simplex virus infection in heart-lung transplant recipients. Transplantation. 1990;49(4):735–9.
18. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis. 2002;34(8):1094–7.
19. Fischer SA, Avery RK, AST Infectious Disease Community of Practice. Screening of donor and recipient prior to solid organ transplantation. Am J Transplant. 2009;9(Suppl 4):S7–18.
20. Humar A, Michaels M, AST ID, Working Group on Infectious Disease Monitoring. American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant. 2006;6(2):262–74.
21. Vu DL, Bridevaux PO, Aubert JD, Soccal PM, Kaiser L. Respiratory viruses in lung transplant recipients: a critical review and pooled analysis of clinical studies. Am J Transplant. 2011;11(5):1071–8.
22. Renaud C, Campbell AP. Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients. Curr Opin Infect Dis. 2011;24(4):333–43.
23. Krunic N, Yager TD, Himsworth D, Merante F, Yaghoubian S, Janeczko R. xTAG RVP assay: analytical and clinical performance. J Clin Virol. 2007;40(Suppl 1):S39–46.
24. Mahony JB. Nucleic acid amplification-based diagnosis of respiratory virus infections. Expert Rev Anti-Infect Ther. 2010;8(11):1273–92.
25. Kuyipers J, Campbell AP, Cent A, Corey L, Boecht M. Comparison of conventional and molecular detection of respiratory viruses in hematopoietic cell transplant recipients. Transpl Infect Dis. 2009;11(4):298–303.
26. Balada-Llasat JM, LaRue H, Kelly C, Rigali L, Pancholi P. Evaluation of commercial ResPlex II v2.0, MultiCode-PLx, and xTAG respiratory viral panels for the diagnosis of respiratory viral infections in adults. J Clin Virol. 2011;50(1):42–5.
27. Berry M, Gamjieldi J, Fielding BC. Identification of new respiratory viruses in the new millennium. Viruses. 2015;7(3):996–1019.
28. Pavia AT. Viral infections of the lower respiratory tract: old viruses, new viruses, and the role of diagnosis. Clin Infect Dis. 2011;52(Suppl 4):S284–9.
29. Wright B, Gross JJ, Kilburn FL, Smith AC. State of the art: research in nursing education administration. J Nurs Educ. 1992;31(9):423–4.
30. Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant. 2007;26(2):271–81.
31. Cooper JD, Billingham M, Egan T, Hertz MI, Higenbottam T, Lynch J, Mauer J, Paradis I, Patterson GA, Smith C, et al. A working formulation for the standardization of nomenclature and for clinical staging of chronic dysfunction in lung allografts. International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 1993;12(5):713–6.
32. Keenan RJ, Lega ME, Dummer JS, Paradis IL, Dauber JH, Rabinowich H, Yousem SA, Hardesty RL, Griffith BP, Duquesnoy RJ, et al. Cytomegalovirus serologic status and postoperative infection correlated with risk of developing chronic rejection after pulmonary transplantation. Transplantation. 1991;51(2):433–8.
33. Palmer SM Jr, Henshaw NG, Howell DN, Miller SE, Davis RD, Tapson VF. Community respiratory viral
infection in adult lung transplant recipients. Chest. 1998;113(4):944–50.
34. Bridges ND, Spray TL, Collins MH, Bowles NE, Towbin JA. Adenovirus infection in the lung results in graft failure after lung transplantation. J Thorac Cardiovasc Surg. 1998;116(4):617–23.
35. Garantziotis S, Howell DN, McAdams HP, Davis RD, Henshaw NG, Palmer SM. Influenza pneumonia in lung transplant recipients: clinical features and association with bronchiolitis obliterans syndrome. Chest. 2001;119(4):1277–80.
36. Vilchez RA, McCurry K, Dauber J, Iacono A, Griffith B, Fung J, Kusne S. Influenza virus infection in adult solid organ transplant recipients. Am J Transplant. 2002;2(3):287–91.
37. Billings JL, Hertz MI, Savik K, Wendt CH. Respiratory viruses and chronic rejection in lung transplant recipients. J Heart Lung Transplant. 2002;21(5):559–66.
38. Massad MG, Ramirez AM. Influenza pneumonia in thoracic organ transplant recipients: what can we do to avoid it? Chest. 2001;119(4):997–9.
39. Faul JL, Akindipe OA, Berry GJ, Theodore J. Influenza pneumonia in a paediatric lung transplant recipient. Transpl Int. 2000;13(1):79–81.
40. Holt ND, Gould FK, Taylor CE, Harwood JF, Freeman R, Healy MD, Corris PA, Dark JH. Incidence and significance of noncytomegalovirus viral respiratory infection after adult lung transplantation. J Heart Lung Transplant. 1997;16(4):416–9.
41. Vilchez RA, McCurry K, Dauber J, Iacono A, Keenan R, Zeevi A, Griffith B, Kusne S. The epidemiology of parainfluenza virus infection in lung transplant recipients. Clin Infect Dis. 2001;33(12):2004–8.
42. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, Danziger-Isakov L, Humar A. Transplantation Society International CMV Consensus Group. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation. 2010;89(7):779–95.
43. Vilchez R, McCurry K, Dauber J, Iacono A, Keenan R, Griffith B, Kusne S. Influenza and parainfluenza respiratory viral infection requiring admission in adult lung transplant recipients. Transplantation. 2002;73(7):1075–8.
44. Colvin BL, Thomson AW. Chemokines, their receptors, and transplant outcome. Transplantation. 2002;74(2):149–55.
45. Hall CB. Respiratory syncytial virus and parainfluenza virus. N Engl J Med. 2001;344(25):1917–28.
46. Skoner DP, Gentile DA, Patel A, Doyle WJ. Evidence for cytokine mediation of disease expression in adults experimentally infected with influenza A virus. J Infect Dis. 1999;180(1):10–4.
47. Arnold R, Humbert B, Werchou H, Gallati H, König W. Interleukin-8, interleukin-6, and soluble tumour necrosis factor receptor type I release from a human pulmonary epithelial cell line (A549) exposed to respiratory syncytial virus. Immunology. 1994;82(1):126–33.
48. Subauste MC, Jacoby DB, Richards SM, Proud D. Infection of a human respiratory epithelial cell line with rhinovirus. Induction of cytokine release and modulation of susceptibility to infection by cytokine exposure. J Clin Invest. 1995;96(1):549–57.
49. Matsukura S, Kokubu F, Noda H, Tokunaga H, Adachi M. Expression of IL-6, IL-8, and RANTES on human bronchial epithelial cells, NCI-H292, induced by influenza virus A. J Allergy Clin Immunol. 1996;98(6 Pt 1):1080–7.
50. Bruder JT, Kovesdi I. Adenovirus infection stimulates the Raf/MAPK signaling pathway and induces interleukin-8 expression. J Virol. 1997;71(1):398–404.
51. Karp CL, Wysocka M, Wahl LM, Ahearn JM, Cuomo PJ, Sherry B, Trinchieri G, Griffin DE. Mechanism of suppression of cell-mediated immunity by measles virus. Science. 1996;273(5272):228–31.
52. Weigt SS, Derhovanessian A, Liao E, Hu S, Gregson AL, Kubak BM, Saggar R, Saggar P, Plachyevski V, Fishbein MC, Lynch JP III, Ardahali A, Ross DJ, Wang HJ, Elashoff RM, Belperio JA. CXCR3 chemokine ligands during respiratory viral infections predict lung allograft dysfunction. Am J Transplant. 2012;12(2):477–84.
53. Kohlmeier JE, Cookenham T, Miller SC, Roberts AD, Christensen JP, Thomsen AR, Woodland DL. CXCR3 directs antigen-specific effector CD4+ T cell migration to the lung during parainfluenza virus infection. J Immunol. 2009;183(7):4378–84.
54. Lindell DM, Lane TE, Lukacs NW. CXCL10/CXCR3-mediated responses promote immunity to respiratory syncytial virus infection by augmenting dendritic cell and CD8(+) T cell efficacy. Eur J Immunol. 2008;38(8):2168–79.
55. Belperio JA, Keane MP, Burdick MD, Lynch JP III, Xue YY, Li K, Ross DJ, Strieter RM. Critical role for CXCR3 chemokine biology in the pathogenesis of bronchiolitis obliterans syndrome. J Immunol. 2002;169(2):1037–49.
56. Belperio JA, Keane MP, Burdick MD, Lynch JP III, Zisman DA, Xue YY, Li K, Ardhalia A, Ross DJ, Strieter RM. Role of CXCL9/CXCR3 chemokine biology during pathogenesis of acute lung allograft rejection. J Immunol. 2003;171(9):4844–52.
57. Zamora MR. Cytomegalovirus and lung transplantation. Am J Transplant. 2004;4(8):1219–26.
58. Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation. 1995;59(3):313–8.
59. Humar A, Snydman D, Snydman D, AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant. 2009;9(Suppl 4):S78–86.
60. SivaSai KS, Smith MA, Poindexter NJ, Sundaarshen SR, Tullock EP, Lynch JP, Cooper JD, Patterson GA, Mohanakumar T. Indirect recognition of donor HLA class I peptides in lung transplant recipients with bronchiolitis obliterans syndrome. Transplantation. 1999;67(8):1094–8.
61. Lemstrom K, Koskinen P, Krogerus L, Daemen M, Bruggeman C, Häyry P. Cytomegalovirus antigen expression, endothelial cell proliferation, and intimal thickening in rat cardiac allografts after cytomegalovirus infection. Circulation. 1995;92(9):2594–604.

62. Community-Acquired Respiratory Viruses. Am J Transplant. 2004;4(s10):105–9.

63. Garibaldi RA. Epidemiology of community-acquired respiratory tract infections in adults. Incidence, etiology, and impact. Am J Med. 1985;78(6B):32–7.

64. Kumar D, Erdman D, Keshavjee S, Peret T, Tellier PO, Lawrence EC. Efficacy of oral ribavirin in lung transplant patients with respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2009;28(1):67–71.

65. Billings JL, Hertz MI, Wendt CH. Community respiratory virus infections following lung transplantation: clinical features and long-term consequences. Semin Thorac Cardiovasc Surg. 2004;16(4):342–9.

66. Remund KF, Best M, Egan JJ. Infections relevant to lung transplantation. Proc Am Thorac Soc. 2009;6(1):94–100.

67. Shah PD, McDyer JF. Viral infections in lung transplant recipients. Semin Respir Crit Care Med. 2010;31(2):243–54.

68. Billings JL, Hertz MI, Wendt CH. Community respiratory virus infections following lung transplantation. Transpl Infect Dis. 2001;3(3):138–48.

69. Hall CB, Powell KR, MacDonald NE, Gala CL, Menegus ME, Sufﬁn SC, Cohen HJ. Respiratory syncytial viral infection in children with compromised immune function. N Engl J Med. 1986;315(2):77–81.

70. Wendt CH, Fox JM, Hertz MI. Paramyxovirus infection in lung transplant recipients. J Heart Lung Transplant. 1995;14(3):479–85.

71. Wendt CH. Community respiratory viruses: organ transplant recipients. Am J Med. 1997;102(3A):48–52; discussion 53–4.

72. Ison MG. Respiratory viral infections in transplant recipients. Antivir Ther. 2007;12(4 Pt B):627–38.

73. Chakinala MM, Walter MJ. Community acquired respiratory viral infections after lung transplantation: clinical features and long-term consequences. Semin Thorac Cardiovasc Surg. 2004;16(4):342–9.

74. Shah PD, McDyer JF. Viral infections in lung transplant recipients. Semin Respir Crit Care Med. 2010;31(2):243–54.

75. McCurdy LH, Milstone A, Dummer S. Clinical features and outcomes of paramyxoviral infection in lung transplant recipients treated with ribavirin. J Heart Lung Transplant. 2003;22(7):745–53.

76. Hopkins P, McNeil K, Kermeen F, Musk M, McQueen E, Mackay I, Sloots T, Nissen M. Human metapneumovirus in lung transplant recipients and comparison to respiratory syncytial virus. Am J Respir Crit Care Med. 2008;178(8):876–81.

77. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ, Finberg RW. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol. 2000;1(5):398–401.

78. Sha Q, Truong-Tran AQ, Plitt JR, Beck LA, Schleimer RP. Activation of airway epithelial cells by toll-like receptor agonists. Am J Respir Cell Mol Biol. 2004;31(3):358–64.

79. Delgado MF, Coviello S, Monsalvo AC, et al. Lack of antibody afﬁnity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med. 2009;15(1):34–41.

80. Graham BS, Rutigliano JA, Johnson TR. Respiratory syncytial virus immunobiology and pathogenesis. Virology. 2002;297(1):1–7.

81. Crowe JE Jr, Williams JV. Immunology of viral respiratory tract infection in infancy. Paediatr Respir Rev. 2003;4(2):112–9.

82. Manuel O, Estabrook M, Estabrook M, AST Infectious Diseases Community of Practice. RNA respiratory viruses in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):212–9.

83. Glanville AR, Scott AI, Morton JM, Aboyou CL, Plit ML, Carter IW, Malouf MA. Intravenous ribavirin is a safe and cost-effective treatment for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2005;24(12):2114–9.

84. Hynicka LM, Ensor CR. Prophylaxis and treatment of respiratory syncytial virus in adult immunocompromised patients. Ann Pharmacother. 2012;46(4):558–66.

85. Pelaez A, Lyon GM, Force SD, Ramirez AM, Neujahr DC, Foster M, Naik PM, Gal AA, Mitchell PO, Lawrence EC. Eﬃcacy of oral ribavirin in lung transplant patients with respiratory syncytial virus lower respiratory tract infection. J Heart Lung Transplant. 2009;28(1):67–71.

86. Li L, Avery R, Budev M, Mossad S, Danziger-Isakov L. Oral versus inhaled ribavirin therapy for respiratory syncytial virus infection after lung transplantation. J Heart Lung Transplant. 2012;31(8):839–44.

87. Burrows FS, Carlos LM, Benzimra M, Marriott DJ, Havryk AP, Plit ML, Malouf MA, Glanville AR. Oral ribavirin for respiratory syncytial virus infection after lung transplantation: efficacy and cost-efﬁciency. J Heart Lung Transplant. 2015;34(7):958–62.

88. Flynn JD, Akers WS, Jones M, Stevkovic N, Waid T, Mullett T, Jahania S. Treatment of respiratory syncytial virus disease. Nat Med. 2009;15(1):34–41.

89. ClinicalTrials.gov [Internet]. Bethesda (MD); National Library of Medicine (US). 2010 Feb 5. Identifier NCT01065935, Phase 2b Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV); 2012
15 Respiratory Viruses and Other Relevant Viral Infections in the Lung Transplant Recipient

99. Kuo JH, Hwang R. Preparation of DNA dry powder for non-viral gene delivery by spray-freeze drying: effect of protective agents (polyethyleneimine and sugars) on the stability of DNA. J Pharm Pharmacol. 2004;56(1):27–33.

100. Hohlfeld J, Niedermeyer J, Hamm H, Schäfers HJ, Wagner H, Fabel H. Seasonal onset of bronchiolitis obliterans syndrome in lung transplant recipients. J Heart Lung Transplant. 1996;15(9):888–94.

101. Armstrong C. ACIP releases recommendations for influenza vaccination, 2015-2016. Am Fam Physician. 2015;92(8):732–40.

102. Relenza® (zanamivir) [package insert]. Research Park, NC: GlaxoSmithKline; 2013.

103. Tamiflu® (oseltamivir) [package insert]. Foster City, CA: Roche; 2008.

104. Rapivab® (peramivir) [package insert]. Durham, NC: BioCryst Pharmaceuticals; 2014.

105. Centers for Disease Control and Prevention, N.C.I.D.E.N. Influenza antiviral medications: summary for clinicians. 2016 5/26/2016 6/27/2016.

106. Kaiser L, Aubert JD, Pache JC, Defernez C, Rochat T, Garbino J, Wunderli W, Meylan P, Yerly S, Perrin L, Letovance I, Nicod L, Tapparel C, Soccal PM. Chronic rhinoviral infection in lung transplant recipients. J Am J Respir Crit Care Med. 2006;174(12):1392–9.

107. Martino R, Porras RP, Rabella N, Williams JV, Rámila E, Margall N, Labeaga R, Crowe JE Jr, Coll P, Sierra J. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant. 2005;11(10):781–96.

108. van Kraaij MG, van Elden LJ, van Loon AM, Hendriksen KA, Laterveer L, Dekker AW, Nijhuis M. Frequent detection of respiratory viruses in adult recipients of stem cell transplants with the use of real-time polymerase chain reaction, compared with viral culture. Clin Infect Dis. 2005;40(5):662–9.

109. Roghmann M, Ball K, Erdman D, Lovchik J, Anderson LJ, Edelman R. Active surveillance for respiratory virus infections in adult recipients of stem cell transplants. Bone Marrow Transplant. 2003;32(11):1085–8.

110. Ison MG, Hayden FG, Kaiser L, Corey L, Boechk M. Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia. Clin Infect Dis. 2003;36(9):1139–43.

111. Hassan IA, Chopra R, Swindell R, Mutton KJ. Respiratory viral infections after bone marrow/peripheral stem cell transplantation: the Christie hospital experience. Bone Marrow Transplant. 2003;32(1):73–7.

112. Ghosh S, Champlin R, Couch R, Englund J, Raad I, Malik S, Luna M, Whimbey E. Rhinovirus infections in myelosuppressed adult blood and marrow transplant recipients. Clin Infect Dis. 1999;29(3):528–32.

113. Michaels MG, Green M, Wald ER, Starzl TE. Adenovirus infection in pediatric liver transplant recipients. J Infect Dis. 1992;165(1):170–4.
114. Ohori NP, Michaels MG, Jaffe R, Williams P, Yousem SA. Adenovirus pneumonia in lung transplant recipients. Hum Pathol. 1995;26(10):1073–9.
115. Kojaoghlanian T, Flemenberg P, Horwitz MS. The impact of adenovirus infection on the immunocompromised host. Rev Med Virol. 2003;13(3):155–71.
116. Howard DS, Phillips GL IL, Reece DE, Munn RK, Henslee-Downey J, Pittard M, Barker M, Pomeroy C. Adenovirus infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 1999;29(6):1494–501.
117. Carrigan DR. Adenovirus infections in immunocompromised patients. Am J Med. 1997;102(3A):71–4.
118. Ison MG. Adenovirus infections in transplant recipients. Clin Infect Dis. 2006;43(3):331–9.
119. Simsir A, Greenebaum E, Schulman LL. Late fatal adenovirus pneumonitis in a lung transplant recipient. Transplantation. 1998;65(4):592–4.
120. Florescu DF, Hoffman JA, AST Infectious Diseases Community of Practice. Adenovirus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):206–11.
121. Vistide® (cidofovir) [package insert]. Foster City, CA: Gilead Sciences; 2010.
122. Heugel J, Martin ET, Kuypers JJ, Englund JA. Coronavirus-associated pneumonia in previously healthy children. Pediatr Infect Dis J. 2007;26(8):753–5.
123. Pene F, Meloni F, Cascarini A, Ciccocioppo R, Piralla A, Baldanti F. Persistent human cosavirus infection in lung transplant recipient. Italy. Emerg Infect Dis. 2013;19(10):1667–9.
124. Campanini G, Rovida F, Meloni F, Cascarini A, Ciccocioppo R, Piralla A, Baldanti F. Persistent human cosavirus infection in lung transplant recipient. Emerg Infect Dis. 2003;37(7):929–32.
125. Bastien N, et al. Human Bocavirus infection, Canada. Emerg Infect Dis. 2006;12(5):848–50.
126. Schenk T, Strahm B, Konnuy U, Hufnagel M, Neumann-Haefelin D, Falcone V. Disseminated bocavirus infection after stem cell transplantation. Emerg Infect Dis. 2007;13(9):1425–7.
127. Miyakis S, van Hal SJ, Barratt J, Stark D, Marriott D, Harkness J. Absence of human Bocavirus in bronchoalveolar lavage fluid of lung transplant patients. J Clin Virol. 2009;44(2):179–80.
128. Snyder LD, Finlen-Copeland CA, Turbyfill WI, Howell D, Willner DA, Palmer SM. Cytopemgalovirus pneumonitis is a risk for bronchiolitis obliterans syndrome in lung transplantation. Am J Respir Crit Care Med. 2010;181(12):1391–6.
129. Patel N, Snyder LD, Finlen-Copeland A, Palmer SM. Is prevention the best treatment? CMV after lung transplantation. Am J Transplant. 2012;12(3):539–44.
130. Mitsani D, Nguyen MH, Girmita DM, Spichy K, Kwak EJ, Silveira FP, Toyoda Y, Pilewski JM, Crespo M, Bham A, Abdel-Massih R, Zaldonis D, Zeevi A, Clancy CJ. A polymorphism linked to elevated levels of interferon-gamma is associated with an increased risk of cytomegalovirus disease among Caucasian lung transplant recipients at a single center. J Heart Lung Transplant. 2011;30(5):523–9.
131. Duncan SR, Paradis IL, Yousem SA, Similo SL, Girruit WF, Williams PA, Dauber JH, Griffith BP. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis. 1992;146(6):1419–25.
132. Torre-Cisneros J. Toward the individualization of cytomegalovirus control after solid-organ transplantation: the importance of the “individual pathogenic balance”. Clin Infect Dis. 2009;49(8):1167–8.
133. Zuk DM, Humer A, Weinkauf JG, Lien DC, Nador RG, Kumar D. An international survey of cytomegalovirus management practices in lung transplantation. Transplantation. 2010;90(6):672–6.
134. Lisboa LF, Kumar D, Wilson LE, Humer A. Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia. Transplantation. 2012;93(2):195–200.
135. Kumar D, Cherkenko S, Moussa G, Cobos I, Oma O, Preiksaitis J, Venkataraman S, Humer A. Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant. 2009;9(5):1214–22.
136. Razonable RR, Humer A, AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):93–106.
137. Clark NM, Lynch JP III, Sayah D, Belperio JA, Fishbein MC, Weigt SS. DNA viral infections complicating lung transplantation. Semin Respir Crit Care Med. 2013;34(3):380–404.
138. Asberg A, Humer A, Jardine AG, Rollag H, Pescoizvic MD, Mousa H, Bignamini A, Töz H, Dittmer I, Montejo M, Hartmann A, VICTOR Study Group. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant. 2009;9(5):1205–13.
139. Cytovene® (ganciclovir) [package insert]. San Francisco, CA: Genentech; 2010.
140. Valcyte® (valganciclovir) [package insert]. San Francisco, CA: Genentech; 2015.
141. Lucas GM, Ross MJ, Stock PG, Shipak MG, Wyatt CM, Gupta SK, Atta MG, Woolks-Kaloustan K, Pham PA, Bruggeman LA, Lennox JL, Ray PE, Kalayjian RC, HIV Medicine Association of the Infectious Diseases Society of America. Clinical practice guideline for the management of chronic kidney disease in patients infected with HIV: 2014 update by the HIV Medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(9):e96–138.
Avery R. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med. 2010;152(12):761–9.

143. Ramanan P, Razonable RR. Cytomegalovirus infections in solid organ transplantation: a review. Infect Chemother. 2013;45(3):260–71.

144. Carraro E, Perosa AH, Siqueira I, Pasternak J, Martino MD. Rotavirus infection in children and adult patients attending in a tertiary Hospital of Sao Paulo, Brazil. Braz J Infect Dis. 2008;12(1):44–6.

145. Le Page AK, Jager MM, Iwasenko JM, Scott GM, Carraro E, Perosa AH, Siqueira I, Pasternak R. Cytomegalovirus infection in children -7 after lung and heart-lung transplantation. J Heart Lung Transplant. 2007;26(1):41–7.

146. Avery RK, Mossad SB, Poggio E, Lard M, Budev M, Bolwell B, Waldman WJ, Braun W, Mawhorter SD, Fatica R, Krishnamurthi V, Young JB, Shrestha R, Stephany B, Lurain N, Yen-Lieberman B. Utility of leflunomide in the treatment of complex cytomegalovirus syndromes. Transplantation. 2010;90(4):419–26.

147. Snydman DR. Leflunomide: a small step forward in meeting the urgent need for treatment of drug-resistant cytomegalovirus infection. Transplantation. 2010;90(4):362–3.

148. ClinicalTrials.gov [Internet]. Bethesda (MD); National Library of Medicine (US). 2012 Jun 1. Identifier NCT01611974, Maribavir for Treatment of Resistant or Refractory CMV Infections in Transplant Recipients; 2012 July; [3 page]. https://clinicaltrials.gov/ct2/show/study/NCT01611974?term=maribavir&rank=2.

149. ClinicalTrials.gov [Internet]. Bethesda (MD); National Library of Medicine (US). 2015 May 7. Identifier NCT02439957, SURPASS: a randomized, double-blind, multicenter study of the efficacy, safety, and tolerability of brincidofovir versus valganciclovir for the prevention of cytomegalovirus (CMV) disease in CMV seropositive kidney transplant recipients (BCV CMV vGCV) (BCV CMV vGCV) ; 2015 September; [3 page]. https://clinicaltrials.gov/ct2/show/record/NCT02439957?term=cm x001&rank=14.

150. Gottschalk S, Rooney CM, Heslop HE. Post-transplant lymphoproliferative disorders. Annu Rev Med. 2005;56:29–44.

151. Manuel O, Kumar D, Singer LG, Cobos I, Humar A. Incidence and clinical characteristics of herpes zoster after lung transplantation. J Heart Lung Transplant. 2008;27(1):11–6.

152. Reams BD, McAdams HP, Howell DN, Steele MP, Davis RD, Palmer SM. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest. 2003;124(4):1242–9.

153. Stevens SJ, Verschuuren EA, Pronk I, van Der Bij W, Harmse MC, The TH, Meijer CJ, van Den Brule AJ, Middeldorp JM. Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients. Blood. 2001;97(5):1165–71.

154. Green M, Michaels MG. Epstein-Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant. 2013;13(Suppl 3):41–54; quiz 54.

155. Kumarasinghe G, Lavee O, Parker A, Nivison-Smith I, Milliken S, Dodds A, Joseph J, Fay K, Ma DD, Malouf M, Plit M, Havryk A, Keogh AM, Hayward CS, Kotlyar E, Jabbour A, Glanville AR, Macdonald PS, Moore JJ. Post-transplant lymphoproliferative disease in heart and lung transplantation: defining risk and prognostic factors. J Heart Lung Transplant. 2015;34(11):1406–14.

156. Pergam SA, Limaye AP, AST Infectious Diseases Community of Practice. Varicella zoster virus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):138–46.

157. Wilck MB, Zuckerman RA, AST Infectious Diseases Community of Practice. Herpes simplex virus in solid organ transplantation. Am J Transplant. 2013;13(Suppl 4):121–7.

158. Zovirax® (acyclovir sodium) for Injection [package insert]. Research Triangle Park, NC: Glaxo Smith Kline; 2003.

159. Zovirax® (acyclovir) [package insert]. Research Triangle Park, NC: Glaxo Smith Kline; 2005.

160. Valtrex® (valacyclovir) [package insert]. Research Triangle Park, NC: Glaxo Smith Kline; 2008.

161. Famvir® (famiclovir) [package insert]. East Hanover, NJ: Novartis; 2011.

162. Lehto JT, Halme M, Tukiainen P, Harjula A, Sipponen J, Lautenschlager I. Human herpesvirus-6 and -7 after lung and heart-lung transplantation. J Heart Lung Transplant. 2007;26(1):41–7.

163. Sathy SJ, Martinu T, Youens K, Lawrence CM, Howell DN, Palmer SM, Steele MP. Symptomatic pulmonary allograft Kaposi’s sarcoma in two lung transplant recipients. Am J Transplant. 2008;8(9):1951–6.

164. Sleiman C, Mal H, Roué C, Groussard O, Baldeyrou P, Olivier P, Fournier M, Pariente R. Bronchial Kaposi’s sarcoma after lung transplantation. Eur Respir J. 1997;10(5):1181–3.

165. Kantor R, Mayan H, Shalmon B, Reichert N, Malouf M, Plit M, Havryk A, Keogh AM, Hayward CS, Kotlyar E, Jabbour A, Glanville AR, Macdonald PS, Moore JJ. Post-transplant lymphoproliferative disease in heart and lung transplantation: defining risk and prognostic factors. J Heart Lung Transplant. 2015;34(11):1406–14.

166. Tereza Martinu DH, Reidy M, Palmer S. Disseminated Kaposi sarcoma in a lung transplant recipient with pulmonary, pleural, and cutaneous involvement. Chest conference 2006; 2006.

167. Kedes DH, Ganem D. Sensitivity of Kaposi’s sarcoma to HHV-8 lytic drugs. Implications for potential therapy. J Clin Invest. 1997;99(9):2082–6.

168. Mocroft A, Youle M, Gazzard B, Morcinek J, Halai R, Phillips AN. Anti-herpesvirus treatment and risk of Kaposi’s sarcoma in HIV infection. Royal Free/
169. Glesby MJ, Hoover DR, Weng S, Graham NM, Phair JP, Detels R, Ho M, Saah AJ. Use of antiviral drugs and the risk of Kaposi's sarcoma: data from the Multicenter AIDS Cohort Study. J Infect Dis. 1996;173(6):1477–80.

170. Thomas LD, Vilchez RA, White ZS, Zanwar P, Milstone AP, Butel JS, Dummer S. A prospective longitudinal study of polyomavirus shedding in lung-transplant recipients. J Infect Dis. 2007;195(3):442–9.

171. Doucette KE, Pang XL, Jackson K, Burton I, Carbonneau M, Cockfield S, Preiksaitis JK. Prospective monitoring of BK polyomavirus infection early posttransplantation in nonrenal solid organ transplant recipients. Transplantation. 2008;85(12):1733–6.

172. Schwarz A, Mengel M, Haller H, Niedermeyer J. Polyoma virus nephropathy in native kidneys after lung transplantation. Am J Transplant. 2005;5(10):2582–5.

173. Thomas LD, Milstone AP, Vilchez RA, Zanwar P, Butel JS, Dummer JS. Polyomavirus infection and its impact on renal function and long-term outcomes after lung transplantation. Transplantation. 2009;88(3):360–6.

174. Viswesh V, Yost SE, Kaplan B. The prevalence and implications of BK virus replication in non-renal solid organ transplant recipients: a systematic review. Transplant Rev (Orlando). 2015;29(3):175–80.

175. Kariyawasam HH, Gyi K, Hodson M, Cohen B. Anaemia in lung transplant patient caused by parvovirus B19. Thorax. 2000;55(7):619–20.

176. Heegaard ED, Petersen BL, Heilmann CJ, Hornsleth A. Prevalence of parvovirus B19 and parvovirus V9 DNA and antibodies in paired bone marrow and serum samples from healthy individuals. J Clin Microbiol. 2002;40(3):933–6.

177. Jordan J, Tiangco B, Kiss J, Koch W. Human parvovirus B19: prevalence of viral DNA in volunteer blood donors and clinical outcomes of transfusion recipients. Vox Sang. 1998;75(2):97–102.